Validation of a portable monitoring device for the diagnosis of obstructive sleep apnea: electrocardiogram-based cardiopulmonary coupling

• DOI: 10.1007/s11325-019-01922-3
• Publication Date: 2019-08-13T23:04:33Z
• Authors: Mi Lu; Fang Fang; John E. Sanderson; Chenyao Ma; Qianqian Wang; Xiaojun Zhan; Fei Xie; Lei Xiao; Hu Liu; Hongyan Liu; Yongxiang Wei
• Keywords: Electrocardiography; Sleep Apnea, Obstructive; 03 medical and health sciences; 0302 clinical medicine; Polysomnography; Humans; Heart; Equipment Design; Lung; Mobile Applications; 3. Good health

We aimed to evaluate the validity of the cardiopulmonary coupling (CPC) device, a limited-channel portable monitoring device for obstructive sleep apnea (OSA) screening in one single-center cohort, in particular in those with some cardiovascular diseases since the cardiopulmonary coupling might be different from those without.Consecutive patients referred to the sleep medical center for assessment of possible OSA were enrolled in this study. Patients were examined with standard polysomnography (PSG) and CPC evaluation simultaneously. The results of the two examinations were compared in all subjects and in those with or without cardiovascular abnormalities.A total of 179 subjects suspected with OSA were finally analyzed. According to OSA severity degree based on AHI, the area under ROC curve for the CPC device in the whole cohort patients was 0.79 (mild), 0.79 (moderate), and 0.86 (severe OSA), respectively (all p < 0.001). For patients with cardiovascular disease with different OSA severity, the area under the ROC curve was 0.86 (mild), 0.73 (moderate), and 0.83 (severe OSA), respectively (all p < 0.0001), and 0.74 (mild), 0.85 (moderate), and 0.91 (severe OSA), respectively in patients without cardiovascular disease (all p < 0.0001).The overall performance of CPC technique was acceptable to assess OSA in subjects with clinical suspicion of OSA, and thus it might act as a fast tool to screen OSA patients. However, the sensitivity of CPC technology for patients with cardiovascular disease was relatively insufficient. Therefore, CPC technology should be carefully interpreted in OSA screening in those with cardiovascular disease.